▶ 調査レポート

神経障害性鎮痛薬の世界市場2020年:企業別、地域別、種類・用途別

• 英文タイトル:Global Neuropathic Pain Drugs Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。神経障害性鎮痛薬の世界市場2020年:企業別、地域別、種類・用途別 / Global Neuropathic Pain Drugs Market 2020 by Company, Regions, Type and Application, Forecast to 2025 / D0GIR-01687資料のイメージです。• レポートコード:D0GIR-01687
• 出版社/出版日:GlobalInfoResearch / 2020年9月23日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、106ページ
• 納品方法:Eメール
• 産業分類:医療、製薬、バイオ
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、神経障害性鎮痛薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。神経障害性鎮痛薬の種類別市場規模(三環系抗うつ薬、抗けいれん薬、セロトニン-ノルエピネフリン再取り込み阻害剤、カプサイシンクリーム、局所麻酔、オピオイド、ステロイド、その他)、用途別市場規模(病院薬局、小売薬局、オンライン薬局)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Pfizer、Baxter Healthcare、GlaxoSmithKline、Johnson & Johnson、Biogen、Sanofi、Bristol-Myers Squibb、Eli Lilly、Depomed
・地域別グローバル市場分析 2015年-2020年
・神経障害性鎮痛薬の北米市場(アメリカ、カナダ、メキシコ)
・神経障害性鎮痛薬のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・神経障害性鎮痛薬のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・神経障害性鎮痛薬の南米市場(ブラジル、アルゼンチン)
・神経障害性鎮痛薬の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:三環系抗うつ薬、抗けいれん薬、セロトニン-ノルエピネフリン再取り込み阻害剤、カプサイシンクリーム、局所麻酔、オピオイド、ステロイド、その他
・用途別分析:病院薬局、小売薬局、オンライン薬局
・地域別市場規模予測 2021年-2025年
・調査の結果・結論

Market Overview
The global Neuropathic Pain Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Neuropathic Pain Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Neuropathic Pain Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Neuropathic Pain Drugs market has been segmented into:
Tricyclic Anti-Depressants Anticonvulsants
Serotonin-Norepinephrine Reuptake Inhibitor
Capsaicin Cream
Local Anaesthesia
Opioids
Steroids
Others

By Application, Neuropathic Pain Drugs has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neuropathic Pain Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Neuropathic Pain Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neuropathic Pain Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Neuropathic Pain Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Neuropathic Pain Drugs Market Share Analysis
Neuropathic Pain Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neuropathic Pain Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neuropathic Pain Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Neuropathic Pain Drugs are:
Pfizer
Baxter Healthcare
GlaxoSmithKline
Johnson & Johnson
Biogen
Sanofi
Bristol-Myers Squibb
Eli Lilly
Depomed

レポート目次

Table of Contents

1 Neuropathic Pain Drugs Market Overview
1.1 Product Overview and Scope of Neuropathic Pain Drugs
1.2 Classification of Neuropathic Pain Drugs by Type
1.2.1 Global Neuropathic Pain Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Neuropathic Pain Drugs Revenue Market Share by Type in 2019
1.2.3 Tricyclic Anti-Depressants Anticonvulsants
1.2.4 Serotonin-Norepinephrine Reuptake Inhibitor
1.2.5 Capsaicin Cream
1.2.6 Local Anaesthesia
1.2.7 Opioids
1.2.8 Steroids
1.2.9 Others
1.3 Global Neuropathic Pain Drugs Market by Application
1.3.1 Overview: Global Neuropathic Pain Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Neuropathic Pain Drugs Market by Regions
1.4.1 Global Neuropathic Pain Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Neuropathic Pain Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Neuropathic Pain Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Neuropathic Pain Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Neuropathic Pain Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Neuropathic Pain Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Neuropathic Pain Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Neuropathic Pain Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 Baxter Healthcare
2.2.1 Baxter Healthcare Details
2.2.2 Baxter Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Baxter Healthcare SWOT Analysis
2.2.4 Baxter Healthcare Product and Services
2.2.5 Baxter Healthcare Neuropathic Pain Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 GlaxoSmithKline SWOT Analysis
2.3.4 GlaxoSmithKline Product and Services
2.3.5 GlaxoSmithKline Neuropathic Pain Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Johnson & Johnson
2.4.1 Johnson & Johnson Details
2.4.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Johnson & Johnson SWOT Analysis
2.4.4 Johnson & Johnson Product and Services
2.4.5 Johnson & Johnson Neuropathic Pain Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Biogen
2.5.1 Biogen Details
2.5.2 Biogen Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Biogen SWOT Analysis
2.5.4 Biogen Product and Services
2.5.5 Biogen Neuropathic Pain Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Sanofi SWOT Analysis
2.6.4 Sanofi Product and Services
2.6.5 Sanofi Neuropathic Pain Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 Bristol-Myers Squibb
2.7.1 Bristol-Myers Squibb Details
2.7.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Bristol-Myers Squibb SWOT Analysis
2.7.4 Bristol-Myers Squibb Product and Services
2.7.5 Bristol-Myers Squibb Neuropathic Pain Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Eli Lilly SWOT Analysis
2.8.4 Eli Lilly Product and Services
2.8.5 Eli Lilly Neuropathic Pain Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Depomed
2.9.1 Depomed Details
2.9.2 Depomed Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Depomed SWOT Analysis
2.9.4 Depomed Product and Services
2.9.5 Depomed Neuropathic Pain Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Neuropathic Pain Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Neuropathic Pain Drugs Players Market Share
3.2.2 Top 10 Neuropathic Pain Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Neuropathic Pain Drugs Revenue and Market Share by Regions
4.2 North America Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
5 North America Neuropathic Pain Drugs Revenue by Countries
5.1 North America Neuropathic Pain Drugs Revenue by Countries (2015-2020)
5.2 USA Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
6 Europe Neuropathic Pain Drugs Revenue by Countries
6.1 Europe Neuropathic Pain Drugs Revenue by Countries (2015-2020)
6.2 Germany Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
6.4 France Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Neuropathic Pain Drugs Revenue by Countries
7.1 Asia-Pacific Neuropathic Pain Drugs Revenue by Countries (2015-2020)
7.2 China Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
7.5 India Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
8 South America Neuropathic Pain Drugs Revenue by Countries
8.1 South America Neuropathic Pain Drugs Revenue by Countries (2015-2020)
8.2 Brazil Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Neuropathic Pain Drugs by Countries
9.1 Middle East & Africa Neuropathic Pain Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Neuropathic Pain Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Neuropathic Pain Drugs Market Forecast by Type (2019-2024)
10.3 Tricyclic Anti-Depressants Anticonvulsants Revenue Growth Rate (2015-2025)
10.4 Serotonin-Norepinephrine Reuptake Inhibitor Revenue Growth Rate (2015-2025)
10.5 Capsaicin Cream Revenue Growth Rate (2015-2025)
10.6 Local Anaesthesia Revenue Growth Rate (2015-2025)
10.7 Opioids Revenue Growth Rate (2015-2025)
10.8 Steroids Revenue Growth Rate (2015-2025)
10.9 Others Revenue Growth Rate (2015-2025)
11 Global Neuropathic Pain Drugs Market Segment by Application
11.1 Global Neuropathic Pain Drugs Revenue Market Share by Application (2015-2020)
11.2 Neuropathic Pain Drugs Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacies Revenue Growth (2015-2020)
11.4 Retail Pharmacies Revenue Growth (2015-2020)
11.5 Online Pharmacies Revenue Growth (2015-2020)
12 Global Neuropathic Pain Drugs Market Size Forecast (2021-2025)
12.1 Global Neuropathic Pain Drugs Market Size Forecast (2021-2025)
12.2 Global Neuropathic Pain Drugs Market Forecast by Regions (2021-2025)
12.3 North America Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
12.6 South America Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Neuropathic Pain Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neuropathic Pain Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neuropathic Pain Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Neuropathic Pain Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Neuropathic Pain Drugs Major Business
Table 7. Pfizer Neuropathic Pain Drugs Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Neuropathic Pain Drugs Product and Solutions
Table 10. Pfizer Neuropathic Pain Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Baxter Healthcare Corporate Information, Location and Competitors
Table 12. Baxter Healthcare Neuropathic Pain Drugs Major Business
Table 13. Baxter Healthcare Neuropathic Pain Drugs Total Revenue (USD Million) (2018-2019)
Table 14. Baxter Healthcare SWOT Analysis
Table 15. Baxter Healthcare Neuropathic Pain Drugs Product and Solutions
Table 16. Baxter Healthcare Neuropathic Pain Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. GlaxoSmithKline Corporate Information, Location and Competitors
Table 18. GlaxoSmithKline Neuropathic Pain Drugs Major Business
Table 19. GlaxoSmithKline Neuropathic Pain Drugs Total Revenue (USD Million) (2017-2018)
Table 20. GlaxoSmithKline SWOT Analysis
Table 21. GlaxoSmithKline Neuropathic Pain Drugs Product and Solutions
Table 22. GlaxoSmithKline Neuropathic Pain Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Johnson & Johnson Corporate Information, Location and Competitors
Table 24. Johnson & Johnson Neuropathic Pain Drugs Major Business
Table 25. Johnson & Johnson Neuropathic Pain Drugs Total Revenue (USD Million) (2017-2018)
Table 26. Johnson & Johnson SWOT Analysis
Table 27. Johnson & Johnson Neuropathic Pain Drugs Product and Solutions
Table 28. Johnson & Johnson Neuropathic Pain Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Biogen Corporate Information, Location and Competitors
Table 30. Biogen Neuropathic Pain Drugs Major Business
Table 31. Biogen Neuropathic Pain Drugs Total Revenue (USD Million) (2017-2018)
Table 32. Biogen SWOT Analysis
Table 33. Biogen Neuropathic Pain Drugs Product and Solutions
Table 34. Biogen Neuropathic Pain Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Sanofi Corporate Information, Location and Competitors
Table 36. Sanofi Neuropathic Pain Drugs Major Business
Table 37. Sanofi Neuropathic Pain Drugs Total Revenue (USD Million) (2017-2018)
Table 38. Sanofi SWOT Analysis
Table 39. Sanofi Neuropathic Pain Drugs Product and Solutions
Table 40. Sanofi Neuropathic Pain Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 42. Bristol-Myers Squibb Neuropathic Pain Drugs Major Business
Table 43. Bristol-Myers Squibb Neuropathic Pain Drugs Total Revenue (USD Million) (2017-2018)
Table 44. Bristol-Myers Squibb SWOT Analysis
Table 45. Bristol-Myers Squibb Neuropathic Pain Drugs Product and Solutions
Table 46. Bristol-Myers Squibb Neuropathic Pain Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Eli Lilly Corporate Information, Location and Competitors
Table 48. Eli Lilly Neuropathic Pain Drugs Major Business
Table 49. Eli Lilly Neuropathic Pain Drugs Total Revenue (USD Million) (2017-2018)
Table 50. Eli Lilly SWOT Analysis
Table 51. Eli Lilly Neuropathic Pain Drugs Product and Solutions
Table 52. Eli Lilly Neuropathic Pain Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Depomed Corporate Information, Location and Competitors
Table 54. Depomed Neuropathic Pain Drugs Major Business
Table 55. Depomed Neuropathic Pain Drugs Total Revenue (USD Million) (2017-2018)
Table 56. Depomed SWOT Analysis
Table 57. Depomed Neuropathic Pain Drugs Product and Solutions
Table 58. Depomed Neuropathic Pain Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Global Neuropathic Pain Drugs Revenue (Million USD) by Players (2015-2020)
Table 60. Global Neuropathic Pain Drugs Revenue Share by Players (2015-2020)
Table 61. Global Neuropathic Pain Drugs Revenue (Million USD) by Regions (2015-2020)
Table 62. Global Neuropathic Pain Drugs Revenue Market Share by Regions (2015-2020)
Table 63. North America Neuropathic Pain Drugs Revenue by Countries (2015-2020)
Table 64. North America Neuropathic Pain Drugs Revenue Market Share by Countries (2015-2020)
Table 65. Europe Neuropathic Pain Drugs Revenue (Million USD) by Countries (2015-2020)
Table 66. Asia-Pacific Neuropathic Pain Drugs Revenue (Million USD) by Countries (2015-2020)
Table 67. South America Neuropathic Pain Drugs Revenue by Countries (2015-2020)
Table 68. South America Neuropathic Pain Drugs Revenue Market Share by Countries (2015-2020)
Table 69. Middle East and Africa Neuropathic Pain Drugs Revenue (Million USD) by Countries (2015-2020)
Table 70. Middle East and Africa Neuropathic Pain Drugs Revenue Market Share by Countries (2015-2020)
Table 71. Global Neuropathic Pain Drugs Revenue (Million USD) by Type (2015-2020)
Table 72. Global Neuropathic Pain Drugs Revenue Share by Type (2015-2020)
Table 73. Global Neuropathic Pain Drugs Revenue Forecast by Type (2021-2025)
Table 74. Global Neuropathic Pain Drugs Revenue by Application (2015-2020)
Table 75. Global Neuropathic Pain Drugs Revenue Share by Application (2015-2020)
Table 76. Global Neuropathic Pain Drugs Revenue Forecast by Application (2021-2025)
Table 77. Global Neuropathic Pain Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Neuropathic Pain Drugs Picture
Figure 2. Global Neuropathic Pain Drugs Revenue Market Share by Type in 2019
Figure 3. Tricyclic Anti-Depressants Anticonvulsants Picture
Figure 4. Serotonin-Norepinephrine Reuptake Inhibitor Picture
Figure 5. Capsaicin Cream Picture
Figure 6. Local Anaesthesia Picture
Figure 7. Opioids Picture
Figure 8. Steroids Picture
Figure 9. Others Picture
Figure 10. Neuropathic Pain Drugs Revenue Market Share by Application in 2019
Figure 11. Hospital Pharmacies Picture
Figure 12. Retail Pharmacies Picture
Figure 13. Online Pharmacies Picture
Figure 14. Global Neuropathic Pain Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Neuropathic Pain Drugs Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Neuropathic Pain Drugs Revenue Market Share in 2019
Figure 23. Global Top 10 Players Neuropathic Pain Drugs Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Neuropathic Pain Drugs Revenue Market Share by Regions (2015-2020)
Figure 27. Global Neuropathic Pain Drugs Revenue Market Share by Regions in 2018
Figure 28. North America Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 29. Europe Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 31. South America Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 33. North America Neuropathic Pain Drugs Revenue Market Share by Countries (2015-2020)
Figure 34. North America Neuropathic Pain Drugs Revenue Market Share by Countries in 2019
Figure 35. USA Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 36. Canada Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 38. Europe Neuropathic Pain Drugs Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Neuropathic Pain Drugs Revenue Market Share by Countries in 2019
Figure 40. Germany Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 41. UK Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 42. France Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Russia Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 44. Italy Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Neuropathic Pain Drugs Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Neuropathic Pain Drugs Revenue Market Share by Countries in 2019
Figure 47. China Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 48. Japan Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 49. Korea Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 50. India Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 52. South America Neuropathic Pain Drugs Revenue Market Share by Countries (2015-2020)
Figure 53. South America Neuropathic Pain Drugs Revenue Market Share by Countries in 2019
Figure 54. Brazil Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Neuropathic Pain Drugs Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Neuropathic Pain Drugs Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 59. UAE Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Neuropathic Pain Drugs Revenue and Growth Rate (2015-2020)
Figure 62. Global Neuropathic Pain Drugs Revenue Share by Type (2015-2020)
Figure 63. Global Neuropathic Pain Drugs Revenue Share by Type in 2019
Figure 64. Global Neuropathic Pain Drugs Market Share Forecast by Type (2021-2025)
Figure 65. Global Tricyclic Anti-Depressants Anticonvulsants Revenue Growth Rate (2015-2020)
Figure 66. Global Serotonin-Norepinephrine Reuptake Inhibitor Revenue Growth Rate (2015-2020)
Figure 67. Global Capsaicin Cream Revenue Growth Rate (2015-2020)
Figure 68. Global Local Anaesthesia Revenue Growth Rate (2015-2020)
Figure 69. Global Opioids Revenue Growth Rate (2015-2020)
Figure 70. Global Steroids Revenue Growth Rate (2015-2020)
Figure 71. Global Others Revenue Growth Rate (2015-2020)
Figure 72. Global Neuropathic Pain Drugs Revenue Share by Application (2015-2020)
Figure 73. Global Neuropathic Pain Drugs Revenue Share by Application in 2019
Figure 74. Global Neuropathic Pain Drugs Market Share Forecast by Application (2021-2025)
Figure 75. Global Hospital Pharmacies Revenue Growth Rate (2015-2020)
Figure 76. Global Retail Pharmacies Revenue Growth Rate (2015-2020)
Figure 77. Global Online Pharmacies Revenue Growth Rate (2015-2020)
Figure 78. Global Neuropathic Pain Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Neuropathic Pain Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Neuropathic Pain Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
Figure 82. Europe Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
Figure 84. South America Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Neuropathic Pain Drugs Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel